Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Next Previous
Trial Profile

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atumelnant (Primary) ; Abiraterone acetate; Fludrocortisone; Hydrocortisone; Lidocaine; Methylprednisolone; Prednisone
  • Indications Congenital adrenal hyperplasia; Cushing syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TouCAHn
  • Sponsors Crinetics Pharmaceuticals

Most Recent Events

  • 05 Jan 2026 Results presented in the Crinetics Pharmaceuticals media release.
  • 04 Jan 2026 According to a Crinetics Pharmaceuticals media release, company announced that it will host a conference call and webcast on Monday, January 5, 2026, at 8:30 a.m. ET to disclose topline results from the fourth cohort of the phase 2 trial of atumelnant in congenital adrenal hyperplasia.
  • 10 Oct 2025 Last checked against ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top